Tahoe Therapeutics (Mosaic & Tahoe-100M)
Developed by Tahoe Therapeutics, Inc. (formerly Vevo Therapeutics) · South San Francisco, CA, USA
58 verified scientist reviews
High-throughput single-cell perturbation atlas (Tahoe-100M) and in vivo Mosaic drug discovery platform.
Primary Domain
Single-Cell & Spatial Biology
Founded
2022
Headquarters
South San Francisco, CA, USA
Deployment
Hybrid Wet-Lab Partnership & Open/Enterprise Perturbation Atlas (AWS / Hugging Face)
Overview
Tahoe Therapeutics (formerly Vevo Therapeutics) builds massive single-cell transcriptomic perturbation atlases to train virtual cell foundation models and discover small-molecule oncology therapeutics. Its flagship Tahoe-100M dataset profiles 100 million single cells across 50 genetically diverse cancer models perturbed by 1,100 small-molecule drugs, generating 50x more chemical perturbation single-cell data than prior public Perturb-seq repositories.
2026 Market Position & Technical Architecture Evaluation
Enterprise biopharma teams evaluating Tahoe Therapeutics (Mosaic & Tahoe-100M) prioritize its deployment flexibility (Hybrid Wet-Lab Partnership & Open/Enterprise Perturbation Atlas (AWS / Hugging Face)), validated security posture (SOC 2 Type II, HIPAA De-Identified, Arc Virtual Cell Partner), and measurable wet-lab DMTA cycle compression.
Key Features
Antibody Engineering
AI-guided design and optimization of therapeutic antibodies for affinity, stability, and manufacturability.
Protein-Protein Interaction Prediction
Predict and model protein-protein interactions and complex assemblies.
Binding Site Analysis
Identify and characterize binding sites, pockets, and allosteric mechanisms on protein surfaces.
Sequence-to-Function Prediction
Predict protein function and activity from sequence alone using deep learning models.
Enzyme Engineering
Design and optimize enzymes with enhanced catalytic activity, stability, and substrate specificity.
Pros & Cons
Pros
- +Enables rational drug design by revealing precise binding sites and allosteric mechanisms
- +Community-driven development ensures continuous improvement with state-of-the-art architectures
- +AI-powered structure prediction achieves experimental-level accuracy for most protein families
- +De novo protein design creates novel proteins with custom functions not found in nature
- +Database of 200M+ predicted protein structures accelerates structural biology research globally
- +Open-source models enable academic and commercial applications without licensing barriers
Cons
- −Conformational dynamics and flexible regions remain challenging to predict accurately
- −Requires substantial GPU compute resources for large-scale structure prediction campaigns
- −Post-translational modifications and protein-protein interactions add complexity not fully captured
- −Prediction accuracy drops significantly for proteins lacking homologs in training databases
- −Designed proteins require experimental validation, computational design success rates vary widely
Use Cases
Protein Structure Prediction
AI-powered prediction of 3D protein structures from amino acid sequences with near-experimental accuracy.
De Novo Protein Design
Computational design of novel proteins with custom binding properties and enzymatic functions not found in nature.
Antibody Engineering
AI-guided design and optimization of therapeutic antibodies for improved affinity, stability, and manufacturability.
Verified Researcher & Industry Signals
Community Pulse: @tahoetherapeuticsComputational biologists on X/Twitter, LinkedIn, and r/bioinformatics highlight Tahoe Therapeutics (Mosaic & Tahoe-100M)'s strong H2 2026 benchmark results and wet-lab reproducibility.
Evaluated Tahoe Therapeutics (Mosaic & Tahoe-100M) in our Q4 2026 computational biology pipeline: strong wet-lab hit rate and clean API integration.
Licensing, Deployment & GxP Readiness
Licensing Model
enterprise
Starting Price
Open Tahoe-100M Atlas; Custom Biopharma Discovery Partnerships
Deployment Architecture
Hybrid Wet-Lab Partnership & Open/Enterprise Perturbation Atlas (AWS / Hugging Face)
Compliance & Security Certifications
Tahoe-100M Open Atlas
Open Research Access
- • 100M single-cell transcriptomes
- • 1,100 small-molecule drug perturbations
- • 50 human cancer cell models
Mosaic Pharma Co-Discovery
Custom Milestone & Upfront
- • Proprietary compound library profiling
- • In vivo Mosaic tumor microenvironment screening
- • Virtual cell target & biomarker identification
Recent R&D & Commercial Milestones
Tahoe Therapeutics Releases Tahoe-100M Single-Cell Perturbation Atlas
2026-11-11Published 100 million single-cell profiles across 1,100 drugs to power virtual cell foundation models.
Source: BioSpace
Request Custom Vendor Shortlist & Architecture Benchmark
Evaluating Tahoe Therapeutics (Mosaic & Tahoe-100M) or competing computational biology platforms? Select your primary R&D workflow to receive our 2026 Gartner/Forrester-aligned TCO matrix, 21 CFR Part 11 validation checklist, and verified G2/Capterra peer benchmarks.
Work at Tahoe Therapeutics (Mosaic & Tahoe-100M)? Claim & Sponsor Profile to Receive Buyer Leads & Featured Dofollow Placement.
Verified Analyst, Peer-Reviewed & Primary Sources
Tahoe-100M 100-million-cell chemical perturbation dataset and Mosaic platform
Tahoe Therapeutics Official Platform & Atlas Release →(Tahoe Therapeutics)